Topping-Off Ceremony of 4-Story Research Building at LA BioMed Propels LA County’s 1st Biotech Hub

78,000 SF building to house new bioscience incubator on 11.5-acre campus that with Harbor- UCLA Medical Center and LA BioMed is on track to become the first biotech hub in the County

FDA approves new treatment for sickle cell disease

News provided by U.S. Food and Drug Administration

July 7, 2017

The U.S. Food and Drug Administration today approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.

LA BioMed Launches Commercialization Accelerator Program™ Powered by Larta Institute

Offers Additional Resources to Help its Startups Succeed

LOS ANGELES – (June 16, 2017) – LA BioMed is launching a Commercialization Accelerator Program™ (CAP), designed and implemented by Larta Institute, that will offer LA BioMed’s early stage bioscience companies additional resources to strengthen and speed their innovations to the marketplace, Keith B. Hoffman, PhD, LA BioMed vice president of business development and technology transfer, and Rohit Shukla,  Larta Institute CEO, announced today.

LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

Receives the Rhoda Benham Award from Medical Mycology Society

LA BioMed Sells Royalty Rights to Kybella®

Proceeds to Help Fund Institute’s Groundbreaking Research and New Facilities

LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers. Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness. 

FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell Disease

TORRANCE, Calif., May 24, 2017 /PRNewswire/ -- Emmaus Life Sciences Inc. announced today that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of EndariTM for the treatment of sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date for July 7, 2017.

LA BioMed Sells Royalty Rights to Kybella® - Proceeds to Help Fund Institute’s Groundbreaking Research and New Facilities

LOS ANGELES – (May  18, 2017) – LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers.

Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.